Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)

NCT06305767 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT06305767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06305767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma (MIUC) (INTerpath-005)
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 28, 2024
Completion date
October 20, 2031
Enrollment
230 (estimated)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer